|Poll|March 20, 2015

Hepatic Encephalopathy in Patient With History of Alcohol Abuse

Imaging on a 60-year-old man demonstrates multiple bony lesions in the spine that could indicate metastatic liver cancer. What is the best diagnostic tool to confirm the diagnosis?

A 60-year-old man with a history of heavy alcohol abuse presents with ascites, jaundice, hepatic encephalopathy, and back pain after a recent fall. Imaging demonstrates multiple bony lesions in the spine that could indicate metastatic hepatocellular carcinoma (HCC).

What is the best diagnostic tool to confirm the diagnosis of HCC?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

September 22nd, 2026

AdenoVerse Platform Receives FDA Designation for HPV-Associated Cancers

The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.

$An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.$

September 22nd, 2026

Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS

An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.

September 22nd, 2026

Charting a Career in Brachytherapy While Preparing to Lead ASTRO

Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.

The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.

September 22nd, 2026

Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera

The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.

As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.

September 22nd, 2026

Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs

As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.

September 22nd, 2026

Distinguishing HER2 Mutations From Amplification in NSCLC Testing

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.